Open Access

ARTICLE IN FRENCH

Ollo Roland Somé^1,*, Abdoul Halim Bagué², Damien Konkobo¹, Dieudonné Hien³, Adama Dembélé³, GL Hermann Bélemlilga¹, Valentin Konségré⁴, Nayi Zongo⁵
Oncologie, Vol.24, No.2, pp. 173-184, 2022, DOI:10.32604/oncologie.2022.021250
Abstract Introduction: Breast cancer management in Sub-Saharian Africa, is faced with diagnosis and treatment challenges. This study aims to describe, breast cancers epidemiology in Bobo-Dioulasso, Burkina Faso. Patients and method: A retrospective cohort study was performed from July 01, 2015 to December 31, 2021 in the Souro Sanou university teaching hospital. Histologically confirmed breast cancer patients were included. Clinical aspect, treatment features and outcome data were collected and analyzed. Results: In study time, eight male’s cases (2%) 360 female’s cases among 368 breast cancers cases were included. The mean age was 46.6 ± 12.1 years, ranging from 15 to 90. The… More >

View

1974

Download

930

Open Access

REVIEW

Amir Imran Faisal Hamdi, Johnson Stanslas^*
Oncologie, Vol.24, No.2, pp. 185-194, 2022, DOI:10.32604/oncologie.2022.023629
Abstract KRAS mutations are among the most common oncogenic abnormalities in cancer. Until recently, drug discovery pursuing KRAS did not produce therapeutic benefits for patients. Specific KRAS inhibitors, such as sotorasib and adagrasib, which bind covalently to codon 12 of substituted glycine to cysteine residue of the protein (G12C), have been approved by the FDA recently for the treatment of lung cancers. Binding of these drugs to the protein inhibits the activation of the GDP-bound inactive state to the GTP-bound active state. Phase 1/2 trials have shown potential anti-tumor activity, particularly in patients with previously treated non-small cell lung cancer. Acquired… More >

View

1459

Download

778

Like

1

Open Access

REVIEW

Dariimaa Ganbat^1,2, Bat-Erdene Jugder³, Lkhamaa Ganbat⁴, Miki Tomoeda⁵, Erdenetsogt Dungubat^2,6, Ambaga Miyegombo⁷, Gantsetseg Garmaa⁸, Yoshihisa Takahashi⁶, Ryuji Fukuzawa⁶, Ichiro Mori⁶, Takayuki Shiomi⁶, Akinori Nakata⁹, Yasuhiko Tomita^6,*
Oncologie, Vol.24, No.2, pp. 195-225, 2022, DOI:10.32604/oncologie.2022.022299
Abstract Most cancer cells overexpress the anti-apoptotic protein survivin and display redox dysregulation originating from genotypic and phenotypic alterations. These disturbances contribute to the uncontrolled proliferation, invasion, and chemoresistance of cancer cells, yet they also represent a specific vulnerability that could be exploited therapeutically in selected tumors. YM155 (sepantronium bromide) is a naphthoquinone-containing imidazolebased compound that selectively inhibits survivin expression at the transcriptional and post-transcriptional levels. Here, we performed a systematic review and meta-analysis of clinical studies in which YM155 was administered as monotherapy or combination therapy for patients with cancer. We assessed fully or partially reported clinical outcomes and pharmacological… More >

View

1697

Download

793

Open Access

REVIEW

Robabeh Faghani Baladehi^1,2, Mohammad Yousef Memar¹, Abolfazl Jafari Sales³, Ahad Bazmani^1,4, Javid Sadri Nahand^1,5,6, Parisa Shiri Aghbash^2,7, Hossein Bannazadeh Baghi^1,2,7,*
Oncologie, Vol.24, No.2, pp. 227-245, 2022, DOI:10.32604/oncologie.2022.020648
Abstract The ability of host cells to activate apoptosis is perhaps the most potent weapon for helping cells eliminate viruses. Human papillomaviruses (HPV) activate several pathways, enabling the infected cells to avoid extrinsic and intrinsic apoptosis pathways. The incapacity of prostatic epithelial cells to induce apoptosis leads to the invasive development of prostate cancer. For the pathogenesis of prostate cancer, several risk factors have been reported; for example, some viruses and infectious diseases have been proposed as causative agents for their relation to prostate diseases. According to several studies, high-risk human papillomaviruses cause malignancy by interfering with the apoptotic and inflammatory… More >

View

1867

Download

772

Like

2

Open Access

REVIEW

Haojie Zhang¹, Xiaohong Wang^2,*, Yue Yu², Zhenlin Yang^3,*
Oncologie, Vol.24, No.2, pp. 247-259, 2022, DOI:10.32604/oncologie.2022.020993
Abstract Chemotherapy plays an important role in controlling cancer progression, but the long-term use of chemotherapeutic agents can lead to drug resistance and eventually treatment failure. Therefore, elucidation of the mechanism of drug resistance is the key to solve the problem of chemotherapy resistance. In recent years, exosomes derived from tumor cells have received extensive attention from researchers. In this paper, we reviewed the role and mechanism of exosome-mediated tumor drug resistance in recent years, summarized the related studies of exosome and chemotherapy drug resistance, and focused on several different ways by which exosomes participate in tumor drug resistance. It includes… More >

View

1461

Download

690

Open Access

ARTICLE

Dayu Tian¹, Yang Shi¹, Li Lei¹, Xiangmin Qiu¹, Tao Song^2,*, Qianyin Li^1,*
Oncologie, Vol.24, No.2, pp. 261-282, 2022, DOI:10.32604/oncologie.2022.022838
（This article belongs to the Special Issue: Cancer Immunotherapy)
Abstract Background: Six2, a transcription factor, exerts an oncogenic role in clear cell renal cell carcinoma (ccRCC). Increased Six2 expression could enhance cancer metastasis. However, the regulatory mechanism of Six2 in promoting metastasis remains unclear. The purpose of this study is to analyze the regulatory pattern of Six2 and the potential role of Six2 in the tumor immune microenvironment. Materials and Methods: Firstly, transcriptional data in TCGA-KIRC cohorts was used to analyze the relationship between Six2 expression and clinical information. Secondly, we detect the association between Six2 and the tumor immune microenvironment in ccRCC. Then, we analyzed Six2-related differentially expressed genes… More >

View

1438

Download

728

Open Access

ARTICLE

Xingjun Meng^1,#, Zhihui Cao^2,#, Renfeng Liu^3,#, Kai Zheng⁴, Shuai Ding⁵, Yuefan Gu⁴, Yonghua Chen⁶, Jun Lv⁷, Ping Li⁸, Li Zhou⁹, Wenbo Wang¹⁰, Shiliang Ji¹¹, Hui He^12,*, Hui Yang^9,*
Oncologie, Vol.24, No.2, pp. 283-294, 2022, DOI:10.32604/oncologie.2022.021259
Abstract It is widely accepted that tumor metastasis is the dominant factor leading to cancer-related death. Tumor metastasis is mediated by cell invasion, blood circulation and lymphatic circulation. Paclitaxel, as a common anti-tumor drug and a mitotic inhibitor, promotes microtubule assembly and inhibits microtubule depolymerization. In addition, ticagrelor, an anti-platelet drug, is used to treat acute coronary syndrome. Increasing numbers of studies have reported that platelets can facilitate tumor metastasis. Therefore, inhibiting the effects of platelets can serve as a novel therapeutic strategy for cancer. To explore the effect of anti-tumor and anti-platelet drugs on tumor progression, we chose paclitaxel and… More >

View

1276

Download

549

Open Access

ARTICLE

Yang Chen^1,#, Huan Wu^2,#, Annan Jiao³, Jiabing Tong⁴, Jie Zhu⁵, Mei Zhang¹, Zegeng Li^4,*, Ping Li^1,*
Oncologie, Vol.24, No.2, pp. 295-307, 2022, DOI:10.32604/oncologie.2022.022116
Abstract Objectives: Lung cancer is a common and malignant tumor in adults and ranks first in the incidence and mortality of the top five malignant tumors in China. Our previous studies have shown that QYSL prescription can balance lung cancer mice Th1/Th2 and inhibit tumor cell immune escape. Here, we examined the effects of QYSL on lung cancer associated macrophage and the potential associated mechanism. Methods: C57BL/6 mice were injected with Lewis lung cancer cells and treated with QYSL. FACS, RT-PCR, and western blot were used to examined the effect of QYSL on tumor immune microenvironment. Results: We found QYSL inhibited… More >

View

1519

Download

682

Open Access

ARTICLE

Minxi Rong¹, Yong Li^1,*, Xiaoli Guo^1,*, Tao Zong², Zhiyuan Ma², Penglei Li²
Oncologie, Vol.24, No.2, pp. 309-327, 2022, DOI:10.32604/oncologie.2022.021256
Abstract Objectives: The ERα biological activity prediction model is constructed by the compound molecular data of the anti-breast cancer therapeutic target ERα and its biological activity data, which improves the screening efficiency of anti-breast cancer drug candidates and saves the time and cost of drug development. Methods: In this paper, Ridge model is used to screen out molecular descriptors with a high degree of influence on the biological activity of Erα and divide datasets with different numbers of the molecular descriptors by screening results. Random Forest (RF) is trained by Root Mean Square Error (RMSE) and Coefficient of determination (R²) to… More >

View

1694

Download

796

Open Access

ARTICLE

Yi Chen^1,#, Liyun Huang^1,#, Zuwu Wei¹, Xiaoling Liu¹, Lihong Chen^1,2,*, Bin Wang^1,2,*
Oncologie, Vol.24, No.2, pp. 329-340, 2022, DOI:10.32604/oncologie.2022.022521
Abstract Background: The effective method for predicting prognosis of ICC is still lack. This study aims to establish and verify an effective prognostic nomogram model for intrahepatic cholangiocarcinoma (ICC) after partial hepatectomy. Materials and Methods: A nomogram model was developed in a cohort of 127 patients from January 2015 to December 2019. General clinical characteristics including preoperative physical examination data and postoperative pathological features were obtained. The independent risk factors identified by univariate and multivariate COX proportional hazards regression models were used to construct nomogram model. Predictive accuracy and discriminative ability were determined using a concordance index and a calibration curve.… More >

View

1480

Download

716

Like

1

Open Access

CASE REPORT

Giuseppe Emmanuele Umana^1,*, Gianluca Ferini², Antonio Crea¹, Bipin Chaurasia³, Vishal Chavda⁴, Leonardo Corbino¹, Daniele Franceschini¹, Maria Grazia Tranchina⁵, Marco Fricia¹, Francesca Graziano⁶, Giovanni Federico Nicoletti⁶, Salvatore Cicero¹, Gianluca Scalia⁶
Oncologie, Vol.24, No.2, pp. 341-348, 2022, DOI:10.32604/oncologie.2022.021347
Abstract Concomitant acute epidural hematoma (EDH) and subdural hematoma (SDH) is a rare finding, and its bilateral onset has not yet been reported in literature. We present the first report of a patient affected by post-traumatic concomitant EDH and SDH, with the contralateral, delayed onset of another, associated with meningioma previously treated with gamma knife. A 60-year-old female patient with a history of simple focal seizures with motor symptoms and well-controlled by drugs since childhood, arterial hypertension, and incidental diagnosis of multiple meningiomas was referred to our department after falling down the stairs. Initially, the patient was prescribed gamma knife treatment… More >

View

1637

Download

605

Open Access

CASE REPORT

Mengjie Li^1,#, Jun Wei^2,#, Guihua Xu^3,#, Ying Liu^3,*, Jian Zhu^3,*
Oncologie, Vol.24, No.2, pp. 349-356, 2022, DOI:10.32604/oncologie.2022.022436
Abstract Gastrointestinal stromal tumors (GISTs) are rare neoplasms arising from mesenchymal cells of the digestive tract and abdomen. Only a few isolated cases of giant esophageal GISTs (greater than 5 cm in size) have been reported with clinical features and surgical methods. Radical esophagectomy with negative margins, followed by gastric tube reconstruction, is recommended for giant esophageal GISTs. However, patients undergoing this type of surgery experienced a sharp decrease in food intake (due to the removal of most of the stomach) and were prone to eating regurgitation, resulting in poor quality of life. We describe the case of a 65-year-old man… More >

View

1452

Download

697